Thank you, Madam Chair.
I'd like to thank all of the witnesses for being here today.
My first questions are for Ms. Fralick at Innovative Medicines Canada.
I appreciate your comments today on intellectual property with respect to innovation in biomanufacturing. We know how important it is to get COVID-19 vaccines to developing countries. If it's not intellectual property concerns slowing down the distribution of vaccines to these developed countries, what would you say the issues would be?